<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258713</url>
  </required_header>
  <id_info>
    <org_study_id>ISA05-02</org_study_id>
    <nct_id>NCT00258713</nct_id>
  </id_info>
  <brief_title>A 36-Week Extension to Protocol ISA04-03</brief_title>
  <acronym>SPIRIT</acronym>
  <official_title>A 36-Week Extension to Protocol ISA04-03 to Evaluate the Safety and Efficacy of ISA247 in Patients With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aurinia Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aurinia Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of voclosporin in patients
      with plaque psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a chronic skin condition that can have a significant impact on patient's
      physical and mental well being. The most common form of psoriasis is plaque psoriasis.
      Targeted treatments in psoriasis have been reported recently, yet cyclosporine, a calcineurin
      inhibitor (CNi) remains one of the treatments which has the greatest efficacy. Voclosporin
      represents the possibility of a calcineurin inhibitor which is not only as efficacious as
      cyclosporine A, but also has an improved toxicity profile.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate long-term safety and tolerability of voclosporin</measure>
    <time_frame>Sixty weeks of continuous treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of subjects achieving and/or maintaining a PASI-75</measure>
    <time_frame>Sixty weeks of continuous treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the proportion of subjects achieving and/or maintaining a reduction of 2 points in the SGA</measure>
    <time_frame>Sixty weeks of continuous treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effect of voclosporin on subject quality of life</measure>
    <time_frame>Sixty weeks of continuous treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">309</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voclosporin</intervention_name>
    <description>voclosporin 0.2, 0.3, or 0.4 mg/kg BID</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged 18-66 years inclusive at the time of visit 1.

          -  Diagnosed with plaque psoriasis ≥ 6 months.

          -  Currently participating in study ISA04-03 and completed the study up to and including
             Visit 9 of study ISA04-03.

          -  Not pregnant or nursing of planning to become pregnant during the course of the study

          -  Sexually-active women of child-bearing potential (including those who are &lt; 1 year
             postmenopausal) and sexually-active men who are practicing a highly effective method
             of birth control. A highly effective method of birth control is defined as one that
             results in a low failure rate (i.e., less than 1% per year) when used consistently and
             correctly and will include implants, injectables, combined oral contraceptives,
             double-barrier method, sexual abstinence, or a sterile partner. Sexually-active men
             and women of child-bearing potential should continue to practice contraception as
             outlined above during treatment and for ≥ 3 months after the last dose of voclosporin.

          -  Written informed consent prior to any study related procedures.

          -  Able to keep study appointments and cooperate with all study requirements, in the
             opinion of the investigator.

        Exclusion Criteria:

          -  Has generalized erythrodermic, guttate, or pustular psoriasis.

          -  Have other dermatoses that would interfere with the evaluation of psoriasis, at the
             discretion of the investigator.

          -  A current malignancy or history of malignancy within 5 years or a history of lymphoma
             at any time. Subjects can be enrolled with a history of squamous or basal cell
             carcinoma that has been surgically excised or removed with curettage and
             electrodesiccation.

          -  Has current, uncontrolled bacterial, viral, or fungal infection that requires
             intravenous antibiotics or antifungals.

          -  Has a current streptococcal infection that required oral antibiotics.

          -  A known history of tuberculosis.

          -  Serologic evidence or known latent human immunodeficiency virus (HIV), hepatitis B
             (HBV) or hepatitis C (HCV) virus.

          -  Uncontrolled hypertension as defined as 3 readings of systolic blood pressure ≥ 150 mm
             Hg or diastolic blood pressure ≥ 90 mm Hg.

          -  MDRD GFR ≤ 60 mL/min.

          -  Unstable renal function (variation in GFR ≥ 30%).

          -  Alanine transaminase, aspartate transaminase, or gamma-glutamyl transferase ≥ 3x upper
             limit of normal(ULN).

          -  White blood cell count ≤ 2.8x10 to the ninth power/L.

          -  Triglycerides ≥ 3x ULN.

          -  Is currently taking or requires the following prohibited medications or treatments
             during the treatment period: drugs potentiating the nephrotoxicity of voclosporin such
             as chronic NSAID's or ACE inhibitors, drugs interfering with it's pharmacokinetics;
             drugs considered to contribute to psoriasis flare; or, systemic and topical psoriasis
             medication (including psoralen/ultraviolet A light treatment) that may interfere with
             assessment of study drug efficacy.

          -  Has taken biological agent(s), except flu shots, tetanus shots, or boosters, within 3
             months of the start of treatment. Biological agents include any virus, therapeutic
             serum, toxin, antitoxin, or analogous product applicable to the prevention, treatment,
             or cure of diseases or injuries of man.

          -  A history of clinically defined allergy to cyclosporine or any of the constituents of
             the voclosporin formulation (vitamin E, medium chain triglyceride oil, Tween 40,
             ethanol).

          -  A history of alcoholism or drug addiction within 1 year prior to study entry.

          -  Weighs &lt; 45 kg (99 lbs) or &gt; 140 kg (308 lbs).

          -  A history of disease, including mental/emotional disorder that would interfere with
             the subject's participation in the study, or that might cause the administration of
             ISA247 to pose a significant risk to the subject, in the opinion of the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bissonnette, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Innovaderm Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Langley, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Canada Cutaneous Research Associates Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gilles Lauzon, PhD MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kim Papp, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Probity Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Shear, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ventana Clinical Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S 3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5J 3S9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 0N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 4F8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N5X 2P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Maple</city>
        <state>Ontario</state>
        <zip>L4K 5V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 6P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>North Bay</city>
        <state>Ontario</state>
        <zip>P1B 3Z7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K 1E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7G 2C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Pointe Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Saint Foy</city>
        <state>Quebec</state>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isotechnika Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Gregory CR, Kyles AE, Bernsteen L, Wagner GS, Tarantal AF, Christe KL, Brignolo L, Spinner A, Griffey SM, Paniagua RT, Hubble RW, Borie DC, Morris RE. Compared with cyclosporine, ISATX247 significantly prolongs renal-allograft survival in a nonhuman primate model. Transplantation. 2004 Sep 15;78(5):681-5.</citation>
    <PMID>15371668</PMID>
  </reference>
  <reference>
    <citation>Stalder M, Bîrsan T, Hubble RW, Paniagua RT, Morris RE. In vivo evaluation of the novel calcineurin inhibitor ISATX247 in non-human primates. J Heart Lung Transplant. 2003 Dec;22(12):1343-52.</citation>
    <PMID>14672749</PMID>
  </reference>
  <reference>
    <citation>Abel MD, Aspeslet LJ, Freitag DG, Naicker S, Trepanier DJ, Kneteman NM, Foster RT, Yatscoff RW. ISATX247: a novel calcineurin inhibitor. J Heart Lung Transplant. 2001 Feb;20(2):161.</citation>
    <PMID>11250240</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2005</study_first_submitted>
  <study_first_submitted_qc>November 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2005</study_first_posted>
  <last_update_submitted>September 24, 2008</last_update_submitted>
  <last_update_submitted_qc>September 24, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Huizinga</name_title>
    <organization>Isotechnika</organization>
  </responsible_party>
  <keyword>Randomized Controlled Trials</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Adult</keyword>
  <keyword>Chronic Disease</keyword>
  <keyword>Dermatologic Agents</keyword>
  <keyword>Female</keyword>
  <keyword>Humans</keyword>
  <keyword>Male</keyword>
  <keyword>Middle Aged</keyword>
  <keyword>Severity of Illness Index</keyword>
  <keyword>Treatment Outcome</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Double-Blind Method</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

